> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Technegas
- URL: https://www.fdaweb.com/regulatory-review-period-for-technegas/
- Published: 2024-09-11T12:00:00.000Z
- Updated: 2026-09-14T14:41:00.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5157751

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Cyclomedica Australia’s Technegas (technetium Tc 99m-labeled carbon), indicated for visualization of pulmonary ventilation and evaluation of pulmonary embolism when paired with perfusion imaging. The regulatory review period is 4,322 days, of which 3,039 days occurred during the testing phase and 1,283 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2024-09-11/pdf/2024-20555.pdf?ref=fdaweb.com).